Tier 2 — strong
Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy
Medical oncology (Northwood, London, England)
2010
27(3):919-925
Bibliography
- PubMed
- PMID 19757213
- Funding
- Funding was not established from the accessible source; this is not a declaration of no funding.
- Competing interests
- A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.
Study snapshot
| Design | Two small randomized supportive-care comparisons plus case series |
|---|---|
| Model | Human participants; see population |
| Sample | 78 randomized across two radiotherapy cohorts; 8 additional treated cases |
| Intervention | Berberine 300 mg three times/day during abdominal/pelvic radiotherapy |
| Duration | During radiotherapy; timing differed by cohort |
| Endpoints | Acute radiation intestinal symptom incidence/severity; Supportive-care tolerability |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
